Pluristem Gets FDA's Orphan Drug Nod for Anemia Treatment

Stem cell researcher Pluristem Therapeutics (NASDAQ: PSTI  ) announced that the FDA granted its patented PLacental eXpanded (PLX) cells orphan drug status for the treatment of aplastic anemia, a rare disorder caused by the failure of certain cells in bone marrow to produce red and white blood cells, and platelets. It marks the second time the PLX cells have been given the designation, the first time being in 2011, for the treatment of Buerger's disease.

Conferring orphan drug status on products gives them a seven-year period of exclusivity upon their approval, along with tax credits for certain clinical testing expenses, grants, and other benefits.

Pluristem's CEO Zami Aberman said:

Receiving orphan drug designation for aplastic anemia is an important event for Pluristem as it open pathways for using our PLX cells for additional indications in the field of hematology.

PLacental eXpanded cells are derived from the full-term placenta, which otherwise would be regarded as waste, and then expanded in Pluristem's proprietary bioreactor system that allows for large-scale growth of the cells. Pluristem Therapeutics is a leading developer of placenta-based cell therapies. 


Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2270685, ~/Articles/ArticleHandler.aspx, 9/1/2014 7:41:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement